178 related articles for article (PubMed ID: 36385738)
1. Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.
Muntañola A; Arguiñano-Pérez JM; Dávila J; de Villambrosia SG; Carpio C; Jiménez-Ubieto A; Salar A;
Clin Transl Sci; 2023 Feb; 16(2):305-312. PubMed ID: 36385738
[TBL] [Abstract][Full Text] [Related]
2. REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon
Welslau M; Kubuschok B; Topaly J; Otremba B; Wolff T; Bryn G
Ther Adv Hematol; 2023; 14():20406207231183765. PubMed ID: 37492394
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar.
Courville J; Nastoupil L; Kaila N; Kelton J; Zhang J; Alcasid A; Nava-Parada P
BioDrugs; 2021 Jul; 35(4):459-468. PubMed ID: 34152584
[TBL] [Abstract][Full Text] [Related]
5. The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
Bishton M; Marshall S; Harchowal J; Salles G; Golfier C; Tucci A; Fernández AR; Sanchez Blanco JJ; Bocchia M; Kim S; Lee YN; Zinzani PL
Hematol Oncol; 2022 Aug; 40(3):370-380. PubMed ID: 35168291
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
[TBL] [Abstract][Full Text] [Related]
7. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
8. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
[TBL] [Abstract][Full Text] [Related]
9. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.
Williams ME; Densmore JJ; Pawluczkowycz AW; Beum PV; Kennedy AD; Lindorfer MA; Hamil SH; Eggleton JC; Taylor RP
J Immunol; 2006 Nov; 177(10):7435-43. PubMed ID: 17082663
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
11. Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases.
Jurczak W; Cohen S; Illidge TM; Silva AD; Amersdorffer J
Future Oncol; 2019 Dec; 15(36):4223-4234. PubMed ID: 31718287
[TBL] [Abstract][Full Text] [Related]
12. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.
Pritchard CH; Greenwald MW; Kremer JM; Gaylis NB; Rigby W; Zlotnick S; Chung C; Jaber B; Reiss W;
BMC Musculoskelet Disord; 2014 May; 15():177. PubMed ID: 24884454
[TBL] [Abstract][Full Text] [Related]
13. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
[TBL] [Abstract][Full Text] [Related]
15. Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study.
McBride A; Daniel S; Driessen MT; Szende A; Choudhry A; Tian M; Ariely R; Thompson S
Leuk Res; 2021 Dec; 111():106671. PubMed ID: 34530254
[TBL] [Abstract][Full Text] [Related]
16. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
17. Rapid rituximab infusion, local center experience.
Monem EA; Al-Bahrani B; Mehdi I; Nada A
Gulf J Oncolog; 2013 Jul; 1(14):52-6. PubMed ID: 23996867
[TBL] [Abstract][Full Text] [Related]
18. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
Dakhil S; Hermann R; Schreeder MT; Gregory SA; Monte M; Windsor KS; Hurst D; Chai A; Brewster M; Richards P
Leuk Lymphoma; 2014 Oct; 55(10):2335-40. PubMed ID: 24471908
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
Tony HP; Krüger K; Cohen SB; Schulze-Koops H; Kivitz AJ; Jeka S; Vereckei E; Cen L; Kring L; Kollins D
Arthritis Care Res (Hoboken); 2019 Jan; 71(1):88-94. PubMed ID: 30295429
[TBL] [Abstract][Full Text] [Related]
20. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.
Li Y; Williams ME; Cousar JB; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2007 Sep; 179(6):4263-71. PubMed ID: 17785867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
